Trader: Low Volume ...
Health Care: Drugs
Arqule Inc. (ARQL: NASDAQ)
$5.68 0.15 | 2.71%
06/04/12 - 04:00 PM ET
Company Profile
| Price and Volume | |
|---|---|
| Recent Price | 5.53 |
| 52 Week High | 8.32 |
| 52 Week Low | 3.98 |
| Avg. Daily Vol. (Mil) | 0.55 |
| Beta (3 year) | 1.39 |
| Share Related Items | |
| Mkt Cap (Mil) | 343.97 |
| Shares Out (Mil) | 62.20 |
| Float (Mil) | 40.08 |
| Dividend Information | |
| Yield % | 0.00 |
| Annual Dividend | 0.00 |
| Payout Ratio | 0.00 |
| Financial Strength | |
| Quick Ratio | 1.50 |
| Current Ratio | 1.50 |
| LT Debt/ Equity | 0.00 |
| Total Debt / Equity | 0.06 |
| Valuation Ratios | |
| Price Earnings | n.a. |
| Price/Sales | 8.11 |
| Price/Book | 12.47 |
| Price/Cash Flow | -28.70 |
| Per Share Data | |
| Earnings | -0.24 |
| Sales | 0.68 |
| Book Value | 0.44 |
| Cash Flow | -0.19 |
| Business Summary | |
|---|---|
| ArQule, Inc. is a clinical-stage biotechnology company, which is engaged in the research and development of innovative cancer therapeutics directed toward molecular targets that play critical roles in the development of human cancers. | |
| General Information | |
| 19 Presidential Way
Woburn, MA 01801 |
|
| www.arqule.com | |
| Industry : Drugs | |
| Sector: Health Care | |
| Employees: 103 | |
| CEO: Paolo Pucci | |
| Short Interest | |
| Current Month (Mil) | 2.70 |
| Previous Month (Mil) | 2.30 |
| Short Interest Ratio (Days) | 5.40 |
| Management Effectiveness | |
| Return on Equity | n.a. |
| Return on Assets | -12.80 |
| Return on Investments | -49.00 |
| Profitability | |
| Gross Margin | n.a. |
| EBIT Margin | -31.90 |
| Profit Margin | -32.00 |
Portfolios with ARQL
- Portfolio NameUser Type
- Contributor22 Biopharma Stocks With Br...
- UserGFNN Stockdiagnostics 11
- ContributorStocks Under-$10 Moving Hig...
- Contributor7 Cancer Drug Stocks to Kno...
- UserASCO 2010
- UserDano Boy's List
- User2bullmates Portfolio 1
- UserASCO 2009 Part 2 the end of...
- UserBVF Inc.
- UserASCO is coming...Papers rel...
Latest ARQL Headlines from TheStreet
- ASCO 2012 Live Blog -- Saturday 06.02.12 | 07:06 am
- 22 Biopharma Stocks With Breakout Potential in 2012 05.22.12 | 08:05 am
- ASCO '12 Abstract Dump: Cancer Stocks in Focus (Update) 05.17.12 | 06:05 am
- ASCO '12 Abstract Dump: Cancer Stocks in Focus 05.16.12 | 06:05 pm
- 3 Stocks Under $10 Moving Higher 04.03.12 | 12:04 pm
- 7 Cancer Drug Stocks to Know Right Now 03.14.12 | 09:03 am
- Arqule Inc. Stock Downgraded (ARQL) 11.15.11 | 06:11 am
- Arqule Inc. Stock Upgraded (ARQL) 05.10.11 | 07:05 am
- Stocks Under $10: Soaring Biotech Stock
01.19.11 | 08:01 am - Crystallex International, Sprint Nextel: Early Volume Plays 06.07.10 | 08:06 am
Press Releases for ARQL
- Positive Phase 2 Study Results For Tivantinib In Previously Treated Hepatocellular Carcinoma To Be Presented At ASCO - Business Wire 06.02.12 | 07:06 am
- ArQule, Inc. To Present At Jefferies 2012 Global Healthcare Conferences - Business Wire 05.31.12 | 08:05 am
- ArQule And Daiichi Sankyo Announce Completion Of Patient Recruitment In Phase 3 Clinical Trial Of Tivantinib In Non-Small Cell Lung Cancer - Business Wire 05.18.12 | 07:05 am
- Positive Phase 2 Clinical Data With Tivantinib In Hepatocellular Carcinoma To Be Highlighted In Oral Presentation At 2012 Annual Meeting Of American Society Of Clinical Oncology - Business Wire 05.17.12 | 07:05 am
- ArQule Reports First Quarter 2012 Financial Results - Business Wire 05.03.12 | 07:05 am
- ArQule To Report First Quarter 2012 Financial Results On May 3, 2012 - Business Wire 04.26.12 | 08:04 am
- ArQule Announces Completion Of Common Stock Offering With Full Exercise Of Option To Purchase Additional Shares - Business Wire 04.16.12 | 04:04 pm
- ArQule Prices Public Offering Of Common Stock - Business Wire 04.11.12 | 07:04 am
- ArQule Announces Proposed Public Offering - Business Wire 04.10.12 | 07:04 am
- ArQule Announces Presentations At AACR 102nd Annual Meeting - Business Wire 03.29.12 | 08:03 am
Partner Headlines for ARQL
- Stock Insights: Dendreon, Medtronic, FedEx, ArQule, Rentrak June 4th - Wall St. Cheat Sheet 06.04.12 | 10:06 am
- ArQule Announces Positive Phase 2 Study Results for Tivantinib in Previously Treated Hepatocellular Carcinoma - Benzinga 06.02.12 | 06:06 pm
- Biotechnology Stocks To Watch Ahead Of ASCO 2012: Part 3 - Seeking Alpha 05.25.12 | 08:05 pm
- Zacks #1 Rank Additions for Tuesday - Tale of the Tape - Zacks 05.01.12 | 09:05 am
- Zacks #1 Rank Additions for Monday - Tale of the Tape - Zacks 04.02.12 | 09:04 am
- Company News for January 18, 2012 - Corporate Summary - Zacks 01.18.12 | 10:01 am
- Zacks #1 Rank Additions for Tuesday - Tale of the Tape - Zacks 11.15.11 | 09:11 am
- Zacks #1 Rank Additions for Tuesday - Tale of the Tape - Zacks 10.04.11 | 09:10 am
- Drugs to Watch at ASCO 2011 - Seeking Alpha 06.02.11 | 08:06 am
- Future Biotech Superstars - Seeking Alpha 03.30.11 | 09:03 am
